Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway.
Various receptor protein kinases have been identified as potential targets for glioma; however, response rates in clinical studies have been somewhat disappointing. Targeting the Spleen Tyrosine Kinase (SYK), which acts downstream of a range of oncogenic receptors, may therefore show more promising results 1).